Kindred Biosciences, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Richard Chin
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1555 Bayshore Hwy Ste 200 Burlingame CA United States of America 94010
- IPO Date
- Dec 12, 2013
- CIK
- 0001561743
- Website
- kindredbio.com
- Similar Companies
- Business
- Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Company News
SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations
Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm
KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN
Why Kindred Biosciences Stock Skyrocketed Today
Kindred Biosciences to merge with Elanco Animal Health
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN
KIN Stock Price Increases Over 45% Pre-Market: Why It Happened
Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket
Elanco Announces Agreement to Acquire Kindred Biosciences
Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?
Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI
Kindred Biosciences, Inc. (KIN) CEO Dr. Richard Chin on Q1 2021 Results - Earnings Call Transcript
Kindred Biosciences Announces First Quarter 2021 Financial Results
Kindred Biosciences to Announce First Quarter 2021 Financial Results
Week 18 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Steven Cohen Adopts Stake in Kindred Biosciences
Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2020 Results - Earnings Call Transcript